These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25500433)

  • 1. Why treatments do(n't) work in vitiligo: An autoinflammatory perspective.
    Speeckaert R; Speeckaert MM; van Geel N
    Autoimmun Rev; 2015 Apr; 14(4):332-40. PubMed ID: 25500433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
    Li R; Qiao M; Wang X; Zhao X; Sun Q
    Photodermatol Photoimmunol Photomed; 2017 Jan; 33(1):22-31. PubMed ID: 27696531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
    Kroll TM; Bommiasamy H; Boissy RE; Hernandez C; Nickoloff BJ; Mestril R; Caroline Le Poole I
    J Invest Dermatol; 2005 Apr; 124(4):798-806. PubMed ID: 15816839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical treatment and combination approaches for vitiligo: new insights, new developments.
    Hossani-Madani AR; Halder RM
    G Ital Dermatol Venereol; 2010 Feb; 145(1):57-78. PubMed ID: 20197746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic management of vitiligo.
    Bleuel R; Eberlein B
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1309-1313. PubMed ID: 30335222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo.
    Wang X; McCoy J; Lotti T; Goren A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2623-7. PubMed ID: 25363734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical placental extract: does it increase the efficacy of narrowband UVB therapy in vitiligo?
    Majid I
    Indian J Dermatol Venereol Leprol; 2010; 76(3):254-8. PubMed ID: 20445295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Advanced Therapeutic Approaches to Treat Vitiligo.
    Sharma CK; Sharma M; Aggarwal B; Sharma V
    J Environ Pathol Toxicol Oncol; 2015; 34(4):321-34. PubMed ID: 26756425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment.
    Lee KY; Jeon SY; Hong JW; Choi KW; Lee CY; Choi SJ; Kim JH; Song KH; Kim KH
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):609-16. PubMed ID: 22404745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitiligo: an update on systemic treatments.
    Searle T; Al-Niaimi F; Ali FR
    Clin Exp Dermatol; 2021 Mar; 46(2):248-258. PubMed ID: 33350506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo: an update on current pharmacotherapy and future directions.
    Colucci R; Lotti T; Moretti S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1885-99. PubMed ID: 22835073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo: pathogenetic hypotheses and targets for current therapies.
    Guerra L; Dellambra E; Brescia S; Raskovic D
    Curr Drug Metab; 2010 Jun; 11(5):451-67. PubMed ID: 20540698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood Vitiligo.
    Nicolaidou E; Mastraftsi S; Tzanetakou V; Rigopoulos D
    Am J Clin Dermatol; 2019 Aug; 20(4):515-526. PubMed ID: 30911977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: a retrospective cohort study.
    Yang K; Xiong X; Pallavi G; Ling Y; Ding F; Duan W; Sun W; Ding G; Gong Q; Zhu W; Lu Y
    Int J Dermatol; 2018 Mar; 57(3):324-331. PubMed ID: 29318595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.
    Custurone P; Di Bartolomeo L; Irrera N; Borgia F; Altavilla D; Bitto A; Pallio G; Squadrito F; Vaccaro M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo: An Updated Narrative Review.
    Leung AKC; Lam JM; Leong KF; Hon KL
    Curr Pediatr Rev; 2021; 17(2):76-91. PubMed ID: 33302860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy.
    Lotti T; Hercogova J; Fabrizi G
    Expert Opin Pharmacother; 2015; 16(16):2485-96. PubMed ID: 26372794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical and Maintenance Treatments for Vitiligo.
    Passeron T
    Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of tumor necrosis factor-α in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study.
    Attwa E; Gamil H; Assaf M; Ghonemy S
    Arch Dermatol Res; 2012 Dec; 304(10):823-30. PubMed ID: 22832941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.